Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lansoprazole + calcium carbonate is an oral fixed-dose combination drug under development for the treatment of gastroesophageal reflux disease (GERD) and reflux esophagitis. Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby reducing stomach acidity[1][4][8]. Calcium carbonate acts as an antacid, neutralizing existing stomach acid and providing rapid symptomatic relief. The combination aims to provide both immediate and sustained control of gastric acidity. This product is being developed by Addpharma, a pharmaceutical company based in South Korea[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lansoprazole + calcium carbonate.